4/A: Allarity Therapeutics Director Amends Filing to Correct Stock Option Details

A director of Allarity Therapeutics, Gerald W. McLaughlin, amended a previous filing to correct the expiration and vesting dates of stock options granted to him.

Summary

• Gerald W. McLaughlin, a director at Allarity Therapeutics, Inc., filed an amended Form 4 to correct errors in a previous filing.
• The amendment pertains to stock options granted on January 22, 2025, under the company's 2021 Equity Incentive Plan.
• The original filing incorrectly stated the expiration date as January 22, 2030, and the vesting date as the grant date.
• The corrected filing shows the stock options expire on January 22, 2035, and vest 100% on the anniversary of the grant date, becoming exercisable at that time.
• The stock options represent the right to purchase 25,000 shares of common stock at an exercise price of $1.01.

Sentiment

Score: 7

Explanation: The document is a routine correction of a filing, indicating no significant positive or negative sentiment. It is a necessary administrative action.

Industry Context

This is a standard SEC filing related to changes in beneficial ownership by company insiders, which is common in the biotech industry where equity compensation is frequently used.

Comparison to Industry Standards

• Stock option grants are a common form of compensation for directors and executives in publicly traded companies, particularly in the biotech sector.
• The vesting schedule of 100% on the anniversary of the grant is a fairly standard practice.
• The 10-year expiration period for the options is also within the typical range for such grants.

Stakeholder Impact

• The correction of the filing ensures transparency for shareholders regarding director compensation.

Key Dates

Keywords

stock options, equity incentive plan, beneficial ownership, director, Allarity Therapeutics, Form 4, SEC filing